Merck’s PREVYMIS gets Health Canada’s approval for CMV disease prevention
Pharmaceutical Business Review
APRIL 22, 2024
Merck said that t he study medication was initiated between Day 0 and Day 7 following the kidney transplant and was continued through Week 28, which is approximately 200 days after the transplant. PREVYMIS was administered either orally or intravenously, with the dosage remaining consistent regardless of the administration route.
Let's personalize your content